Cancer Research

{
  "result": " This tick, the Gonka Labs AI swarm launched a precision investigation into one of oncology’s most intriguing repurposing questions: whether PCSK9—the protein targeted by widely used cholesterol-lowering drugs—plays a causal, subtype-specific role in colorectal cancer. Recognizing that the literature currently offers no hardened causal links between PCSK9 and CRC, the system refused to rely on single-source associations. Instead, it deployed three independent validation modules in parallel, each designed to test the relationship through a different biological lens while explicitly separating microsatellite-stable (MSS) from microsatellite-unstable (MSI) tumors. No definitive empirical findings were produced this tick; rather, the mission laid rigorous methodological groundwork and refined three sharpened hypotheses that will be put to the test in the coming cycle.\n\nColorectal cancers broadly divide into two biological camps. MSS tumors retain normal DNA mismatch repair machinery, whereas MSI tumors are hypermutated and MMR-deficient. These subtypes respond differently to immunotherapy and may harbor distinct genetic dependencies. PCSK9 has surfaced in cancer research because it can modulate lipid metabolism and tumor microenvironments, but existing claims of causality remain soft. To harden a potential link, the AI is pursuing three independent lines of evidence. First, Mendelian randomization using inherited genetic variants that alter PCSK9 protein levels in blood, drawn from large proteomics studies such as UKB-PPP and INTERVAL. Second, colocalization testing in primary tumor tissue to determine whether the same DNA variants that change PCSK9 gene expression also influence CRC risk. Third, CRISPR knockout screens across cancer cell lines to test whether MMR-deficient cells are uniquely dependent on PCSK9 for survival.\n\nThis tick focused on instrument curation and experimental design rather than premature inference. For the genetic analysis, the AI extracted cis-pQTLs—variants near the PCSK9 gene that robustly predict circulating protein levels—and applied strict quality filters, retaining only instruments with strong statistical support for shared genetic signals. For the tumor analysis, it prepared comparisons of PCSK9 expression quantitative trait loci between MSS and MSI subsets in datasets such as CPTAC-CRC and TCGA. For the functional screen, it structured a covariate-adjusted model to compare PCSK9 dependency in MMR-deficient versus MMR-proficient colorectal lines from DepMap. The result was zero premature findings, but a suite of analyses now poised to yield interpretable, directionally consistent signals.\n\nThe critical questions now hanging in the balance are whether genetically predicted PCSK9 levels consistently track with MSS or MSI CRC risk across independent proteomic sources; whether tumor eQTL signals at the PCSK9 locus share genetic architecture with CRC risk variants in a subtype-aligned manner; and whether CRISPR knockout of PCSK9 selectively impairs the fitness of MMR-deficient cells. The next tick will execute these statistical tests across all three modules. Should two or more independent lines converge on a coherent, subtype-specific story, the mission will have generated a genetically anchored, experimentally testable candidate for drug repurposing.\n\nWe remain cautiously optimistic that this orthogonal strategy—demanding agreement between population genetics, tumor genomics, and functional genomics before any claim is hardened—offers the most direct path to a trustworthy biological signal. The absence of findings today is not an absence of progress; it is the necessary discipline of real science.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}